ION-464 is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Parkinson's Disease.

1 number Not willing to lag behind SMA gene therapy Zolgensma, Biogen launches high-dose trial of Spinraza BMS's second three-drug regimen, Empliciti, is approved by the European Union to treat ...

Covalent peptide drugs can achieve high potency and selectivity with long dosing intervals, however, methods to discover them are limited. Here, the authors incorporate a genetically encoded ...

sattka mattka final Cumulative financing exceeds US$2.1 billion! GRAIL submits IPO application Biogen releases Spinraza treatment data for presymptomatic SMA: 96% of patients can walk with assistance ...

INR:7277. rummy arrs Priced at RMB 2.37 million per year, SMA treatment drug Spinraza faces new competitor amid controversy Allergan successfully joins the "rich famil ...

Priced at RMB 2.37 million per year, SMA treatment drug Spinraza faces new competitor amid controversy What kind of product ...

INR:7627. odds on that betfair A shot of Biogen's SMA drug costs 700,000 yuan in China and 200 yuan abroad. Why is it so expensive? 9 drug marketing applicat ...

INR:7359. ultimate rummycircle The State Council approved the implementation of the "one business, one license" reform for Shanghai pharmacies Biogen release ...

Jackpot caslno app Anjisheng Biopharma Completes Series A Financing to Advance New Drug Development in Severe Musculoskeletal Diseases Takeda's "Icat ...

INR:8502. best football player in india Medical Device Representatives: 2020 Salary Levels Announced After 40 years of drug supervision, do you supp ...

Drug-resistant infections are most prevalent in critical care units Antibiotics are hailed as medical saviours. But they are increasingly facing a crafty adversary: bacteria that mutate and adapt ...

Born with spinal muscular atrophy (SMA), a rare disease that causes progressive muscle degeneration and weakness, I have ...